Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

BioScience Health Innovations (BHIC) Gross Profit (2023 - 2026)

BioScience Health Innovations has reported Gross Profit over the past 4 years, most recently at $485596.0 for Q1 2026.

  • Quarterly Gross Profit fell 45.81% to $485596.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Mar 2026, up 43.64% year-over-year, with the annual reading at $3.2 million for FY2025, 147.59% up from the prior year.
  • Gross Profit was $485596.0 for Q1 2026 at BioScience Health Innovations, down from $571863.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $1.1 million in Q2 2025 and troughed at $27591.0 in Q1 2023.
  • The 4-year median for Gross Profit is $339009.0 (2024), against an average of $424585.2.
  • Year-over-year, Gross Profit surged 750.87% in 2024 and then plummeted 45.81% in 2026.
  • A 4-year view of Gross Profit shows it stood at $236511.0 in 2023, then surged by 43.34% to $339009.0 in 2024, then soared by 68.69% to $571863.0 in 2025, then decreased by 15.09% to $485596.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Gross Profit are $485596.0 (Q1 2026), $571863.0 (Q4 2025), and $698231.0 (Q3 2025).